Industry's efforts: devices and pharmaceuticals.
The pharmaceutical industry has been irreversibly affected by the changes occurring in healthcare. Despite the obvious contributions of pharmaceuticals to human health, our customers are demanding that we help the patient and contribute to value, whether it be in terms of cost, clinical outcomes, or quality of life. We are learning to balance the variables to ensure that cost plus quality equals value in the marketplace in three ways: by focusing on the needs of the customers and demonstrating value through outcomes research, by maintaining an emphasis on innovation, and by taking an active role in the public arena to direct the course of our future. Outcomes research proves the value of what we do. Economic data will have to be correlated with clinical data. In addition to standard clinical and economic parameters, we must also provide quality of life data. Collaboration between the academic and the practicing community produces a win-win situation for both parties. Industry and practitioners are bonded together ineluctably in the service of the patient. Working together we can shape our future and the future of our patients.
Glaxo Inc, Research Triangle Park, NC 27709, USA.
C A
CA
Sanders
D003362:Cost-Benefit Analysis; D004345:Drug Industry; D004864:Equipment and Supplies; D018166:Health Care Reform; D006301:Health Services Needs and Demand; D006801:Humans; D007221:Industry; D008389:Marketing of Health Services; D017063:Outcome Assessment, Health Care; D011785:Quality Assurance, Health Care / Q000458:organization & administration*; D011788:Quality of Life; D014481:United States